Memphis Pharmaceuticals results, Q1 2024
Net profit, assets, equity and cash flow for Q1 2024, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit24.76 millionEGP · +95.6% vs the same period a year earlier
Total assets796 millionEGP · +45.0% vs the same period a year earlier
Shareholders' equity128 millionEGP · +169.5% vs the same period a year earlier
Operating cash flow137 millionEGP · +156.4% vs the same period a year earlier
In short
- Memphis Pharmaceuticals's net profit for Q1 2024 was about 24.76 million EGP, up +95.6% from 12.66 million EGP in Q1 2023.
- Total assets at the end of Q1 2024 were about 796 million EGP, and shareholders' equity about 128 million EGP.
- Operating cash flow for Q1 2024 was positive at 137 million EGP.
Key lines against the same period a year earlier
This periodQ1 2023Change
Net profit24.76 million12.66 million+95.6%
Gross profit55.09 million49.29 million+11.8%
Total assets796 million549 million+45.0%
Total liabilities668 million501 million+33.1%
Shareholders' equity128 million47.55 million+169.5%
Total liabilities and equity796 million549 million+45.0%
Operating cash flow137 million-243 million+156.4%
Investing cash flow3.31 million561 thousand+489.8%
Financing cash flow—294 million—
Net change in cash141 million51.49 million+173.0%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy